NCT06177067 - Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

July 31, 2026

Conditions

Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaAcute Leukemia of Ambiguous Lineage

Interventions

DRUG

Revumenib

Given by mouth (capsule or liquid solution) or liquid solution by Nasogastric tube (NG) or Gastrostomy tube (G-tube)

DRUG

Venetoclax

Given by mouth (tablet)

DRUG

Azacitidine

Given intravenously (IV) infusion

DRUG

intrathecal (IT) chemotherapy

Given intrathecal (IT)

DRUG

Cytarabine

Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.

DRUG

Methotrexate

Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.

Trial Locations (6)

10065

RECRUITING

Memorial Sloan- Kettering Cancer Center, New York

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

64108

RECRUITING

Children's Mercy Hospital of Kansas City, Kansas City

75390

RECRUITING

UT Southwestern/Simmons Cancer Center, Dallas

92132

RECRUITING

Rady Children's Hospital, San Diego